publication . Article . 2019

Toll‐Like Receptor 9 Plays a Pivotal Role in Angiotensin II–Induced Atherosclerosis

Fukuda, Daiju; Nishimoto, Sachiko; Aini, Kunduziayi; Tanaka, Atsushi; Nishiguchi, Tsuyoshi; Kim‐Kaneyama, Joo‐ri; Lei, Xiao‐Feng; Masuda, Kiyoshi; Naruto, Takuya; Tanaka, Kimie; ...
Open Access English
  • Published: 01 Mar 2019 Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, volume 8, issue 7 (eissn: 2047-9980, Copyright policy)
  • Publisher: John Wiley and Sons Inc.
Abstract
Background Toll‐like receptor (TLR) 9 recognizes bacterial DNA, activating innate immunity, whereas it also provokes inflammation in response to fragmented DNA released from mammalian cells. We investigated whether TLR9 contributes to the development of vascular inflammation and atherogenesis using apolipoprotein E–deficient (Apoe −/−) mice. Methods and Results Tlr9‐deficient Apoe −/− (Tlr9 −/− Apoe −/−) mice and Apoe −/− mice on a Western‐type diet received subcutaneous angiotensin II infusion (1000 ng/kg per minute) for 28 days. Angiotensin II increased the plasma level of double‐stranded DNA, an endogenous ligand of TLR9, in these mice. Genetic deletion or ph...
Subjects
free text keywords: Original Research, Vascular Medicine, atherosclerosis, inflammation, macrophage, Toll‐like receptor 9, vascular inflammation, Basic Science Research, Vascular Biology
44 references, page 1 of 3

1 Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045–2051.22895665 [OpenAIRE] [PubMed]

2 Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91:281–291.12193460 [PubMed]

3 Uematsu S, Akira S. Toll‐like receptors and innate immunity. J Mol Med (Berl). 2006;84:712–725.16924467 [PubMed]

4 Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010;10:826–837.21088683 [OpenAIRE] [PubMed]

5 Zheng Y, Gardner SE, Clarke MC. Cell death, damage‐associated molecular patterns, and sterile inflammation in cardiovascular disease. Arterioscler Thromb Vasc Biol. 2011;31:2781–2786.22096097 [PubMed]

6 Bieghs V, Trautwein C. The innate immune response during liver inflammation and metabolic disease. Trends Immunol. 2013;34:446–452.23668977 [OpenAIRE] [PubMed]

7 Hagerling C, Casbon AJ, Werb Z. Balancing the innate immune system in tumor development. Trends Cell Biol. 2015;25:214–220.25444276 [OpenAIRE] [PubMed]

8 Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak‐Rothstein A. Toll‐like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev. 2005;204:27–42.15790348 [OpenAIRE] [PubMed]

9 Cole JE, Kassiteridi C, Monaco C. Toll‐like receptors in atherosclerosis: a “Pandora's box” of advances and controversies. Trends Pharmacol Sci. 2013;34:629–636.24139612 [PubMed]

10 Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll‐like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002;105:1158–1161.11889007 [PubMed]

11 Vollmer J. TLR9 in health and disease. Int Rev Immunol. 2006;25:155–181.16818370 [PubMed]

12 Mogensen TH, Paludan SR, Kilian M, Ostergaard L. Live Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis activate the inflammatory response through Toll‐like receptors 2, 4, and 9 in species‐specific patterns. J Leukoc Biol. 2006;80:267–277.16731773 [OpenAIRE] [PubMed]

13 Atamaniuk J, Hsiao YY, Mustak M, Bernhard D, Erlacher L, Fodinger M, Tiran B, Stuhlmeier KM. Analysing cell‐free plasma DNA and SLE disease activity. Eur J Clin Invest. 2011;41:579–583.21128939 [PubMed]

14 Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O, Coffman RL. Nucleic acids of mammalian origin can act as endogenous ligands for Toll‐like receptors and may promote systemic lupus erythematosus. J Exp Med. 2005;202:1131–1139.16230478 [OpenAIRE] [PubMed]

15 Roshan MH, Tambo A, Pace NP. The role of TLR2, TLR4, and TLR9 in the pathogenesis of atherosclerosis. Int J Inflam. 2016;2016:1532832.27795867 [OpenAIRE] [PubMed]

44 references, page 1 of 3
Abstract
Background Toll‐like receptor (TLR) 9 recognizes bacterial DNA, activating innate immunity, whereas it also provokes inflammation in response to fragmented DNA released from mammalian cells. We investigated whether TLR9 contributes to the development of vascular inflammation and atherogenesis using apolipoprotein E–deficient (Apoe −/−) mice. Methods and Results Tlr9‐deficient Apoe −/− (Tlr9 −/− Apoe −/−) mice and Apoe −/− mice on a Western‐type diet received subcutaneous angiotensin II infusion (1000 ng/kg per minute) for 28 days. Angiotensin II increased the plasma level of double‐stranded DNA, an endogenous ligand of TLR9, in these mice. Genetic deletion or ph...
Subjects
free text keywords: Original Research, Vascular Medicine, atherosclerosis, inflammation, macrophage, Toll‐like receptor 9, vascular inflammation, Basic Science Research, Vascular Biology
44 references, page 1 of 3

1 Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045–2051.22895665 [OpenAIRE] [PubMed]

2 Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91:281–291.12193460 [PubMed]

3 Uematsu S, Akira S. Toll‐like receptors and innate immunity. J Mol Med (Berl). 2006;84:712–725.16924467 [PubMed]

4 Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010;10:826–837.21088683 [OpenAIRE] [PubMed]

5 Zheng Y, Gardner SE, Clarke MC. Cell death, damage‐associated molecular patterns, and sterile inflammation in cardiovascular disease. Arterioscler Thromb Vasc Biol. 2011;31:2781–2786.22096097 [PubMed]

6 Bieghs V, Trautwein C. The innate immune response during liver inflammation and metabolic disease. Trends Immunol. 2013;34:446–452.23668977 [OpenAIRE] [PubMed]

7 Hagerling C, Casbon AJ, Werb Z. Balancing the innate immune system in tumor development. Trends Cell Biol. 2015;25:214–220.25444276 [OpenAIRE] [PubMed]

8 Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak‐Rothstein A. Toll‐like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev. 2005;204:27–42.15790348 [OpenAIRE] [PubMed]

9 Cole JE, Kassiteridi C, Monaco C. Toll‐like receptors in atherosclerosis: a “Pandora's box” of advances and controversies. Trends Pharmacol Sci. 2013;34:629–636.24139612 [PubMed]

10 Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll‐like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002;105:1158–1161.11889007 [PubMed]

11 Vollmer J. TLR9 in health and disease. Int Rev Immunol. 2006;25:155–181.16818370 [PubMed]

12 Mogensen TH, Paludan SR, Kilian M, Ostergaard L. Live Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis activate the inflammatory response through Toll‐like receptors 2, 4, and 9 in species‐specific patterns. J Leukoc Biol. 2006;80:267–277.16731773 [OpenAIRE] [PubMed]

13 Atamaniuk J, Hsiao YY, Mustak M, Bernhard D, Erlacher L, Fodinger M, Tiran B, Stuhlmeier KM. Analysing cell‐free plasma DNA and SLE disease activity. Eur J Clin Invest. 2011;41:579–583.21128939 [PubMed]

14 Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O, Coffman RL. Nucleic acids of mammalian origin can act as endogenous ligands for Toll‐like receptors and may promote systemic lupus erythematosus. J Exp Med. 2005;202:1131–1139.16230478 [OpenAIRE] [PubMed]

15 Roshan MH, Tambo A, Pace NP. The role of TLR2, TLR4, and TLR9 in the pathogenesis of atherosclerosis. Int J Inflam. 2016;2016:1532832.27795867 [OpenAIRE] [PubMed]

44 references, page 1 of 3
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue